STUDY OF THE ANTITUMOR ACTIVITY OF THE LIPOSOMAL FORM OF THE GLYCOLYSIS INHIBITOR IODOACETATE IN THE LEWIS LUNG CARCINOMA MODEL
Journal: Cardiometry
Year: 2022

The altered glucose metabolism in cancer cells, known as the Warburg effect, is a new area of research of anticancer agents [1]. To date, many compounds have been identified that address the glucose metabolism. However, many of them failed at the early stages of clinical trials, demonstrating systemic toxicity [2, 3]. The glycolysis inhibitor iodoacetate (IA) has a good antitumor effect, but, like other glycolysis inhibitors, it has an unsafe profile. Liposomes (LS) are a good element to provide